PetMed Express Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de PetMed Express han disminuido a una tasa media anual de -35.7%, mientras que en la industria Specialty Retail los beneficios crecieron en un 0.1% anualmente. Los ingresos han ido disminuyendo a una tasa media de 1.8% al año.

Información clave

-35.7%

Tasa de crecimiento de los beneficios

-35.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Specialty Retail	4.1%
Tasa de crecimiento de los ingresos	-1.8%
Rentabilidad financiera	-2.7%
Margen neto	-1.0%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero PetMed Express. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

DB:PQM Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Dec 23	277	-3	73
30 Sep 23	271	-6	70
30 Jun 23	265	-3	65
31 Mar 23	257	5	59
31 Dec 22	259	9	54
30 Sep 22	262	16	53
30 Jun 22	264	19	50
31 Mar 22	272	19	48
31 Dec 21	279	22	49
30 Sep 21	284	25	47
30 Jun 21	292	27	49
31 Mar 21	304	24	51
31 Dec 20	312	31	51
30 Sep 20	306	30	51
30 Jun 20	300	28	50
31 Mar 20	284	26	48
31 Dec 19	274	25	48
30 Sep 19	275	26	48
30 Jun 19	276	31	48
31 Mar 19	283	38	47
31 Dec 18	286	41	45
30 Sep 18	286	43	45
30 Jun 18	282	41	45
31 Mar 18	274	37	44
31 Dec 17	270	35	43
30 Sep 17	262	30	42
30 Jun 17	256	27	41
31 Mar 17	249	24	40
31 Dec 16	242	22	39
30 Sep 16	240	22	40
30 Jun 16	236	21	41
31 Mar 16	235	21	43
31 Dec 15	229	20	43
30 Sep 15	228	20	44
30 Jun 15	228	18	44
31 Mar 15	229	17	46
31 Dec 14	228	17	47
30 Sep 14	229	17	48
30 Jun 14	232	18	48
31 Mar 14	233	18	49
31 Dec 13	236	18	49
30 Sep 13	235	18	49
30 Jun 13	233	18	50

Ingresos de calidad: PQM actualmente no es rentable.

Margen de beneficios creciente: PQM actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: PQM no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 35.7% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de PQM en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: PQM no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Specialty Retail (-15.3%).

Rentabilidad financiera

Alta ROE: PQM tiene una rentabilidad financiera negativa (-2.66%), ya que actualmente no es rentable.

PetMed Express Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

PetMed Express, Inc. to Report Q3, 2024 Results on Feb 08, 2024

Second quarter 2024 earnings released: US$0.003 loss per share (vs US$0.13 profit in 2Q 2023)

PetMed Express, Inc. to Report Q2, 2024 Results on Oct 30, 2023

First quarter 2024 earnings released: US$0.044 loss per share (vs US$0.14 profit in 1Q 2023)

PetMed Express, Inc. to Report Q1, 2024 Results on Jul 31, 2023

Full year 2023 earnings released: EPS: US$0.011 (vs US$1.05 in FY 2022)

Recent updates

PetMed Express, Inc. Announces Executive Changes

PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

PetMed Express, Inc. announced delayed 10-Q filing

PetMed Express, Inc. announced delayed 10-Q filing

PetMed Express, Inc. to Report Q3, 2024 Results on Feb 08, 2024

PetMed Express, Inc. Announces Management Changes

Independent Chairman of the Board recently bought €281k worth of stock

CEO, President & Director recently bought €94k worth of stock

Second quarter 2024 earnings released: US$0.003 loss per share (vs US$0.13 profit in 2Q 2023)

PetMed Express, Inc. Makes Decision to Suspend the Quarterly Dividend Effective the Quarter Ended September 30, 2023

PetMed Express, Inc. to Report Q2, 2024 Results on Oct 30, 2023

Now 21% undervalued after recent price drop

First quarter 2024 earnings released: US$0.044 loss per share (vs US$0.14 profit in 1Q 2023)

PetMed Express, Inc. to Report Q1, 2024 Results on Jul 31, 2023

Now 21% undervalued after recent price drop

High number of new directors

Full year 2023 earnings released: EPS: US$0.011 (vs US$1.05 in FY 2022)

PetMed Express, Inc. Declares a Quarterly Dividend, Payable on June 12, 2023

PetMed Express, Inc., Annual General Meeting, Aug 03, 2023

PetMed Express, Inc. Appoints Sandra Y. Campos to its Board of Directors

PetMed Express, Inc. to Report Q4, 2023 Results on May 22, 2023

Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.21 profit in 3Q 2022)

PetMed Express, Inc. Declares Quarterly Dividend, Payable on February 27, 2023

Investor sentiment improves as stock rises 17%

PetMed Express, Inc. to Report Q3, 2023 Results on Feb 06, 2023

PetMed Express, Inc. entered into an agreement to acquire PetCareRx, Inc. from Evolution VC Partners and Feenix Venture Partners.

PetMed Express, Inc. entered into an agreement to acquire PetCareRx, Inc. from Evolution VC Partners and Feenix Venture Partners.

Second quarter 2023 earnings released: EPS: US$0.13 (vs US$0.32 in 2Q 2022)

PetMed Express, Inc. Declares Quarterly Dividend, Payable on November 30, 2022

PetMed Express, Inc. to Report Q2, 2023 Results on Nov 07, 2022

Now 20% undervalued

Upcoming dividend of US$0.30 per share

First quarter 2023 earnings released: EPS: US$0.14 (vs US$0.22 in 1Q 2022)

Petmed Express, Inc. Declares Quarterly Dividend, Payable on August 19, 2022

PetMed Express, Inc. Announces Executive Changes

PetMed Express, Inc. to Report Q1, 2023 Results on Jul 25, 2022

PetMed Express, Inc., Annual General Meeting, Jul 28, 2022

PetMed Express, Inc., Annual General Meeting, Jul 28, 2022

Full year 2022 earnings released: EPS: US$1.05 (vs US$1.53 in FY 2021)

PetMed Express, Inc. Declares Quarterly Dividend, Payable on May 27, 2022

PetMed Express, Inc. to Report Q4, 2022 Results on May 09, 2022

PetMed Express, Inc. Appoints Diana Garvis Purcel to Board of Directors, Effective April 4, 2022

Upcoming dividend of US$0.30 per share

PetMed Express, Inc. Provides Sales Guidance for the Year 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Second quarter 2022 earnings released: EPS US$0.32 (vs US$0.42 in 2Q 2021)

Independent Director Frank Formica has left the company

First quarter 2022 earnings released: EPS US$0.22 (vs US$0.39 in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS US$1.53 (vs US$1.29 in FY 2020)

Full year 2021 earnings released: EPS US$1.53 (vs US$1.29 in FY 2020)

PetMed Express, Inc. Declares a Quarterly Dividend, Payable on May 21, 2021

Independent Chairman Robert Schweitzer has left the company

PetMed Express, Inc. Announces Executive Changes

Corporate Secretary & General Counsel has left the company

Investor sentiment deteriorated over the past week

CFO & Treasurer recently sold €206k worth of stock

Third quarter 2021 earnings released: EPS US$0.38 (vs US$0.34 in 3Q 2020)

Revenue beats expectations

Revenue beats expectations

Revenue beats expectations

Revenue beats expectations

Third quarter 2021 earnings released: EPS US$0.38

New 90-day high: €28.65

PetMed Express, Inc. to Report Q3, 2021 Results on Jan 19, 2021

New 90-day high: €27.42

Second quarter 2021 earnings released: EPS US$0.42

Revenue misses expectations

Desglose de ingresos y gastos
Beta